The Filing Desk

Harvard Bioscience vs Standard Biotools

Harvard Bioscience HBIO · Standard Biotools LAB · Life Sciences Tools & Services

Harvard Bioscience reported revenue of $86 million in fiscal 2025, about the same as Standard Biotools' $85 million in fiscal 2025. Harvard Bioscience's revenue fell 8.1% in its latest year, and Standard Biotools' fell 6.2%. Harvard Bioscience had an operating margin of -56.1%, against -129.2% at Standard Biotools. Free cash flow was $5 million at Harvard Bioscience and −$83 million at Standard Biotools.

Side by side

Harvard BioscienceStandard Biotools
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$86M$85M
Revenue growth−8.1%−6.2%
Revenue growth a year, last 5 years−3.3%−9.2%
Gross margin57.7%49.9%
Operating margin−56.1%−129.2%
Net margin−65.5%−87.8%
Free cash flow$5M−$83M
Free cash flow margin6.3%−96.8%
Return on capital−56.0%−41.9%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2.0%8.0%
Last close$8.68$0.61
P/E at the last close—1.8×
Insider trades, last 12 monthsbought $202,354, sold $0bought $11.1 million, sold $0
Piotroski F-score3 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Harvard BioscienceStandard Biotools
Operating margin
Percent of revenue
Harvard BioscienceStandard Biotools
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Harvard BioscienceStandard Biotools

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Harvard Bioscience and Standard Biotools pages.